vimarsana.com

Page 7 - தேசிய மெய்நிகர் உயிரி தொழில்நுட்பவியல் ஆய்வகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Students Identify Starting Points for Potential COVID-19 Inhibitors

Virtual drug-discovery internships provide opportunity for hands-on experience with real-world impact December 28, 2020 Students working remotely during virtual fall internships at Brookhaven Lab helped identify molecules that may work to inhibit key functions of the virus that causes COVID-19. This image shows a computational model of a small molecule (blue and red stick figure) bound to the active site of the virus s Papain Like protease (PLpro, the green ribbon background molecule). Two students working under the mentorship of Desigan Kumaran, a structural biologist at the U.S. Department of Energy’s Brookhaven National Laboratory, have helped to identify molecules that could potentially lead to new antiviral drugs for treating COVID-19. Though the students conducted their fall 2020 internships remotely, the potential of their work is firmly planted in the real world and could have lasting impact.

Scientists get the most realistic view yet of a coronavirus spike s protein structure

 E-Mail IMAGE: This rotating image shows the detailed structure of a spike from a coronavirus that causes cold symptoms - a milder relative of the virus that causes COVID-19. Spikes bind to. view more  Credit: K. Zhang et al., Quarterly Reviews of Biophysics Discovery, 2020 Coronaviruses like the one that causes COVID-19 are studded with protein spikes that bind with receptors on the cells of their victims ­- the first step in infection. Now scientists have made the first detailed images of those spikes in their natural state, while still attached to the virus and without using chemical fixatives that might distort their shape.

APS plays foundational role in development of COVID-19 vaccines

 E-Mail IMAGE: Data taken at the APS shows the neutralizing antibody D25 binding to the F protein of the Respiratory Syncytial Virus (RSV). This binding stabilizes the protein in its prefusion form.. view more  Credit: Jason McLellan There is light at the end of the COVID-19 pandemic tunnel. Several vaccines against the SARS-CoV-2 virus that causes COVID-19 are now in clinical trials, with one developed by Pfizer/BioNTech already having been approved for emergency use in the United States. This has been the fastest development and rollout of any vaccine in history, starting with the first gene sequence released in January. (The previous record was held by the mumps vaccine, which took four years.)

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.